Track Evotec SE — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Evotec SE EVT.F · Stock Open Evotec SE in new tab

2.80 EUR
EPS
-1.10
P/B
0.76
ROE
-26.08
Beta
1.31
Target Price
3.73 EUR
Loading chart...
Key Metrics
EPS-1.10
Book Value3.75
Price to Book0.76
Debt/Equity71.50
% Insiders9.966%
Growth
Revenue Growth-0.16%
Estimates
Forward P/E-6.79
Forward EPS-0.42
Target Mean Price3.73

DCF valuation

Model fair value for Evotec SE (EVT.F)
Result
Sign in to run the valuation for EVT.F.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 3.73 EUR (low 3.00, high 5.00)
Low 3.00
Mean 3.73
High 5.00
Price 2.80
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Evotec SE Logo Evotec SE Analysis (EVT.F)

Germany Health Care Official Website Stock

Is Evotec SE a good investment? Evotec SE (EVT.F) is currently trading at 2.80 EUR. Market analysts have a consensus price target of 3.73 EUR. This suggests a potential upside from current levels.

Investor FAQ

Does Evotec SE pay a dividend?

No, it does not currently pay a dividend.

What asset class is Evotec SE?

Evotec SE is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

Company Profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Exchange Ticker
PNK (United States) EVOTF
GER (Germany) EVT.DE
FRA (Germany) EVT.F
STU (Germany) EVT.SG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion